Joined the founding team at seed financing stage, helping build and advance Acrivon through an exclusive license agreement for prexasertib from Eli Lilly, fundraising milestones (Series A, B, IPO,PIPE), a companion diagnostic partnership with Akoya Biosciences, launch of the company's ACR-368 clinical studies, and continued development of the AP3 platform and internal pipeline.

Co-founded a founder-financed immuno-oncology focused biotech with an option agreement to key technology and insights out of MD Anderson Cancer Center.

Working with platform and executive leadership, developing business plans for several Moon Shots initiatives including precision medicine and cell therapy. Scouting for development and commercialization opportunities.

Opsonix is developing pathogen-extracting therapies to transform the treatment of bloodstream infections and sepsis. The company’s proprietary expertise is creating engineered pathogen-capture proteins derived from opsonins, which are natural components of our innate immune system that bind to and help clear all types of infectious pathogens and toxins from our bodies. Opsonix’s lead pathogen-capture protein, FcMBL, is being incorporated into an extracorporeal medical device that treats blood outside the body to remove a broad range of pathogens and toxins responsible for initiating the sepsis cascade without having to first identify the disease-causing agent.

Developed the product development, business, and fundraising strategy for Opsonix, formally launching the company in October 2015 following completion of an $8M Series A financing round.

Led business and strategy development for MD Anderson's Institute for Applied Cancer Science; P&L responsibility for the institution's $75M investment in this dedicated drug discovery and development platform.

Founding employee; led Metamark's efforts in licensing (in- and out-), developing partnerships, and building the IP strategy and portfolio. Forged enabling alliances with HistoRx, Definiens, and a $365 million therapeutic target collaboration with Janssen Biotech.

Member of Flagship's venture creation team. Founding team member of renewable fuels company Joule Unlimited, Inc (fka Joule Biotechnologies) and the therapeutic company concept, NetEffect Pharmaceuticals, Inc..

Served in a variety of scientific and operational leadership roles of increasing responsibility, and led the manufacturing operations team tasked with construction of complex and repetitive DNA sequences.

Research scientist tasked with expanding microRNA detection offerings. Developed and launched the mirVana qRT-PCR miRNA detection kit. Investigated diagnostic and therapeutic applications of miRNAs, contributing to intellectual property forming the basis of two spin-outs, Asuragen and Mirna Therapeutics.

Identified and investigated novel human proteins that interact with HIV-1 proteins. Developed the first described retroviral vector to stably express siRNA in mammalian cells.